Cancers of the blood and lymph system, such as leukemia, lymphoma, and multiple myeloma, are on the rise in adults and are the focus of the Hematologic Malignancies and Bone Marrow Transplant Program. Our scientists are studying cancer stem cells, viruses, genetics and other factors to uncover the biology driving these diseases and improve treatments. Bone marrow transplantation, or the replacement of diseased bone marrow (the blood cell factory) with healthy marrow from a donor or specially-treated marrow from the patient, is often used to treat cancers of the blood, and our researchers are developing and refining techniques in bone marrow graft engineering, mismatched marrow donations, and vaccine approaches to minimize side effects and complications and make this therapy more tolerable and more effective for patients. Program leaders are Drs. Richard Ambinder and Rick Jones.